Keyphrases
Rapid Response
100%
Naïve Patients
100%
Inflammatory Bowel Disease
100%
Vedolizumab
100%
Biologic-naïve
100%
Placebo
60%
Crohn's Disease
60%
Tumor Necrosis Factor Antagonist
60%
Ulcerative Colitis
50%
Stool Frequency
40%
Abdominal Pain
20%
Composite Score
20%
Rectal Bleeding
20%
Patient-reported Symptoms
20%
Loose Stools
20%
Monoclonal Antibody
10%
Clinical Response
10%
Logistic Regression Analysis
10%
Adult Patients
10%
Active Ulcerative Colitis
10%
Phase III Clinical Trial
10%
Change from Baseline
10%
Early Response
10%
Integrin
10%
Previously Treated
10%
Biologic Therapy
10%
Symptom Score
10%
Change Score
10%
Randomized Phase III Trial
10%
Bleeding Frequency
10%
Medicine and Dentistry
Patient with Inflammatory Bowel Disease
100%
Vedolizumab
100%
Placebo
60%
Tumor Necrosis Factor
60%
Patient with Ulcerative Colitis
40%
Crohn's Disease
30%
Patient with Crohn's Disease
30%
Abdominal Pain
20%
Ulcerative Colitis
20%
Rectal Bleeding
20%
Post-Hoc Analysis
20%
Loose Feces
20%
Clinical Trial
10%
Monoclonal Antibody
10%
Randomized Controlled Trial
10%
Multivariate Logistic Regression Analysis
10%
Integrin
10%
Biological Therapy
10%
Neuroscience
Vedolizumab
100%
Inflammatory Bowel Disease
100%
Placebo
60%
Necrosis
60%
Randomized Controlled Trial
10%
Integrin
10%
Monoclonal Antibody
10%